Foulkes W D, Thiffault I, Gruber S B, Horwitz M, Hamel N, Lee C, Shia J, Markowitz A, Figer A, Friedman E, Farber D, Greenwood C M T, Bonner J D, Nafa K, Walsh T, Marcus V, Tomsho L, Gebert J, Macrae F A, Gaff C L, Paillerets B Bressac-De, Gregersen P K, Weitzel J N, Gordon P H, MacNamara E, King M-C, Hampel H, De La Chapelle A, Boyd J, Offit K, Rennert G, Chong G, Ellis N A
Department of Medicine, Sir Mortimer B Davis-Jewish General Hospital, Montreal, Quebec, Canada, H3G 1A4.
Am J Hum Genet. 2002 Dec;71(6):1395-412. doi: 10.1086/345075. Epub 2002 Nov 26.
Hereditary nonpolyposis colorectal cancer (HNPCC) is caused by mutations in the mismatch-repair genes. We report here the identification and characterization of a founder mutation in MSH2 in the Ashkenazi Jewish population. We identified a nucleotide substitution, MSH2*1906G-->C, which results in a substitution of proline for alanine at codon 636 in the MSH2 protein. This allele was identified in 15 unrelated Ashkenazi Jewish families with HNPCC, most of which meet the Amsterdam criteria. Genotype analysis of 18 polymorphic loci within and flanking MSH2 suggested a single origin for the mutation. All colorectal cancers tested showed microsatellite instability and absence of MSH2 protein, by immunohistochemical analysis. In an analysis of a population-based incident series of 686 Ashkenazi Jews from Israel who have colorectal cancer, we identified 3 (0.44%) mutation carriers. Persons with a family history of colorectal or endometrial cancer were more likely to carry the mutation than were those without such a family history (P=.042), and those with colorectal cancer who carried the mutation were, on average, younger than affected individuals who did not carry it (P=.033). The mutation was not detected in either 566 unaffected Ashkenazi Jews from Israel or 1,022 control individuals from New York. In hospital-based series, the 1906C allele was identified in 5/463 Ashkenazi Jews with colorectal cancer, in 2/197 with endometrial cancer, and in 0/83 with ovarian cancer. When families identified by family history and in case series are included, 25 apparently unrelated Ashkenazi Jewish families have been found to harbor this mutation. Although this pathogenic mutation is not frequent in the Ashkenazi Jewish population (accounting for 2%-3% of colorectal cancer in those whose age at diagnosis is <60 years), it is highly penetrant and accounts for approximately one-third of HNPCC in Ashkenazi Jewish families that fulfill the Amsterdam criteria.
遗传性非息肉病性结直肠癌(HNPCC)由错配修复基因的突变引起。我们在此报告在阿什肯纳兹犹太人群体中鉴定出的MSH2基因的一个始祖突变及其特征。我们鉴定出一个核苷酸替换,MSH2*1906G→C,该替换导致MSH2蛋白第636位密码子处的丙氨酸被脯氨酸取代。在15个无亲缘关系的患有HNPCC的阿什肯纳兹犹太家庭中发现了该等位基因,其中大多数家庭符合阿姆斯特丹标准。对MSH2基因内部及侧翼的18个多态性位点进行基因型分析表明该突变起源单一。通过免疫组织化学分析,所有检测的结直肠癌均显示微卫星不稳定性且无MSH2蛋白。在对来自以色列的686名患有结直肠癌的阿什肯纳兹犹太人的基于人群的发病系列分析中,我们鉴定出3名(0.44%)突变携带者。有结直肠癌或子宫内膜癌家族史的人比没有此类家族史的人更有可能携带该突变(P = 0.042),并且携带该突变的结直肠癌患者平均比未携带该突变的患者年龄小(P = 0.033)。在来自以色列的566名未受影响的阿什肯纳兹犹太人和来自纽约的1022名对照个体中均未检测到该突变。在基于医院的系列研究中,在463名患有结直肠癌的阿什肯纳兹犹太人中有5名、197名患有子宫内膜癌的患者中有2名以及83名患有卵巢癌的患者中未发现该1906C等位基因。当将通过家族史鉴定的家庭和病例系列纳入时,已发现25个明显无亲缘关系的阿什肯纳兹犹太家庭携带该突变。尽管这种致病突变在阿什肯纳兹犹太人群体中并不常见(在诊断年龄<60岁的人群中占结直肠癌的2% - 3%),但它具有高度的外显率,在符合阿姆斯特丹标准的阿什肯纳兹犹太家庭中约占HNPCC的三分之一。